Human Genome, Gentium in spotlight
April 01, 2010 at 10:43 AM EDT
Human Genome Sciences is the lead gainer among the larger-cap drug-stock issues in early activity, moving on news that analysts at Jesup and Lamont have initiated coverage of the stock with a buy rating.